Gilead Sciences Acquires CymaBay for $4.3 Billion, Expanding Liver Disease Portfolio

Gilead Sciences has agreed to acquire CymaBay Therapeutics for $4.3 billion, gaining access to an experimental liver disease treatment with potential blockbuster sales. The deal provides Gilead with CymaBay's lead experimental drug, seladelpar, which is under FDA review for potential treatment of primary biliary cholangitis. This acquisition comes as Gilead seeks growth beyond its core HIV business and amidst recent setbacks in clinical trials for other drugs.